Review Articleδ-Opioid Receptor Antagonists as a New Concept for Central Acting Antitussive Drugs
References (20)
- et al.
Modulation of μ-mediated antinociception by δ agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2, D-Pen5]enkephalin
Eur J Pharmacol
(1989) - et al.
Modulation of μ-mediated antinociception by δ agonists: characterization with antagonists
Eur J Pharmacol
(1989) - et al.
Modulation of μ-mediated antitussive activity in rats by δ agonist
Eur J Pharmacol
(1991) - et al.
Differential modulation of μ-opioid receptor-mediated antitussive activity by δ-opioid receptor agonists in mice
Eur J Pharmacol
(1993) - et al.
Antitussive effects of Ca2+ channel antagonists
Eur J Pharmacol
(1992) - et al.
Potentiation of thermoregulatory and analgesic effects of morphine by calcium antagonists
Pharmacol Res Commun
(1984) - et al.
Analgesic effects of several calcium channel blockers in mice
Eur J Pharmacol
(1987) - et al.
Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance
Eur J Pharmacol
(1988) - et al.
Modulation of κ-mediated antitussive activity in rats by a δ agonist
Res Commun Chem Pathol Pharmacol
(1992) - et al.
Differential antagonism of opioid delta antinociception by [D-Ala2, Leu4, Cys6]enkephalin and naltrindole 5-isothiocyanate: evidence for delta receptor subtypes
J Pharmacol Exp Ther
(1991)
There are more references available in the full text version of this article.
Cited by (26)
Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851
2008, Bioorganic and Medicinal ChemistryThe physiology of cough
2006, Paediatric Respiratory ReviewsErratum: The pharmacology of cough (Trends in Pharmacological Sciences (2004) 25 (569-576) DOI: 10.1016/j.tips.2004.09.009
2005, Trends in Pharmacological SciencesModels used in the development of antitussive drugs
2004, Drug Discovery Today: Disease ModelsPotential new cough therapies
2004, Pulmonary Pharmacology and Therapeutics
- f1
Author for correspondence: J. Kamei. Tel: 81-3-5498-5030; Fax: 81-3-5498-5029; E-mail:[email protected]
Copyright © 2002 Elsevier Science Ltd. All rights reserved.